Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Susceptibility

Ivermectin Impairs the Development of Sexual and Asexual Stages of Plasmodium falciparum In Vitro

Lais Pessanha de Carvalho, Thaisa Lucas Sandri, Edésio José Tenório de Melo, Rolf Fendel, Peter G. Kremsner, Benjamin Mordmüller, Jana Held
Lais Pessanha de Carvalho
aInstitute of Tropical Medicine, University of Tübingen, Tübingen, Germany
bGerman Centre for Infection Research, Tübingen, Germany
cLaboratory of Cell and Tissue Biology, Center for Biosciences and Biotechnology, State University of North Fluminense Darcy Ribeiro, Rio de Janeiro, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thaisa Lucas Sandri
aInstitute of Tropical Medicine, University of Tübingen, Tübingen, Germany
bGerman Centre for Infection Research, Tübingen, Germany
dLaboratory of Molecular Immunopathology, Clinical Hospital, Federal University of Paraná, Curitiba, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edésio José Tenório de Melo
cLaboratory of Cell and Tissue Biology, Center for Biosciences and Biotechnology, State University of North Fluminense Darcy Ribeiro, Rio de Janeiro, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rolf Fendel
aInstitute of Tropical Medicine, University of Tübingen, Tübingen, Germany
bGerman Centre for Infection Research, Tübingen, Germany
eCentre de Recherches Médicales de Lambaréné, Lambaréné, Gabon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter G. Kremsner
aInstitute of Tropical Medicine, University of Tübingen, Tübingen, Germany
bGerman Centre for Infection Research, Tübingen, Germany
eCentre de Recherches Médicales de Lambaréné, Lambaréné, Gabon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Benjamin Mordmüller
aInstitute of Tropical Medicine, University of Tübingen, Tübingen, Germany
bGerman Centre for Infection Research, Tübingen, Germany
eCentre de Recherches Médicales de Lambaréné, Lambaréné, Gabon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jana Held
aInstitute of Tropical Medicine, University of Tübingen, Tübingen, Germany
bGerman Centre for Infection Research, Tübingen, Germany
eCentre de Recherches Médicales de Lambaréné, Lambaréné, Gabon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.00085-19
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Ivermectin is the drug of choice for many parasitic infections, with more than one billion doses being distributed in onchocerciasis programs. The drug has been put into focus recently by the malaria community because of its potential to kill blood-sucking mosquitoes, thereby reducing malaria transmission. However, the activity of ivermectin against the malaria parasite itself has been only partly investigated. This study aimed to investigate the in vitro activity of ivermectin against asexual and sexual stages of Plasmodium falciparum. Both asexual and late-stage gametocytes were incubated with ivermectin and control drugs in vitro. The growth-inhibiting effects were assessed for asexual stages of different Plasmodium falciparum laboratory strains and culture-adapted clinical isolates using the histidine-rich protein 2 enzyme-linked immunosorbent assay technique. The effect against stage IV/V gametocytes was evaluated based on ATP quantification. Ivermectin showed activities at nanomolar concentrations against asexual stages (50% inhibitory concentration of ∼100 nM) and stage IV/V gametocytes (500 nM) of P. falciparum. Stage-specific assays suggested that ivermectin arrests the parasite cycle at the trophozoite stage. Ivermectin might add a feature to its “wonder drug” properties with activity against asexual stages of the malaria parasite Plasmodium falciparum. The observed activities might be difficult to reach with current regimens but will be more relevant with future high-dose regimens under investigation. Further studies should be performed to confirm these results in vitro and in vivo.

INTRODUCTION

Ivermectin, a mixture of two semisynthetic analogs, is a macrocyclic lactone derived from avermectin B1, a compound that is naturally produced by the bacterium Streptomyces avermitilis; it is considered one of the most successful drugs discovered (1). It acts robustly at low doses, with a broad spectrum of activity against nematodes, insects, and acarine parasites, and has a very good safety profile (2). Ivermectin was discovered in the early 1970s and was licensed in 1981 as an antiparasitic drug for animal health (3); since 1987, it has been used to treat onchocerciasis in affected human populations around the tropics (4). Ivermectin has shown unprecedented versatility, safety, and benefits primarily in the world`s poorest areas (5). Currently, ivermectin is used to treat other tropical diseases, such as onchocerciasis, lymphatic filariasis, and strongyloidiasis (2), and it is also active against scabies and lice (6, 7). Recently, ivermectin has been under investigation as a complementary tool for blocking and controlling malaria transmission (8, 9).

Malaria is a mosquito-borne parasitic disease, with approximately 219 million cases resulting in 435,000 deaths worldwide in 2017 (10) and with the greatest burden in sub-Saharan Africa, especially in young children (11). Five species of Plasmodium can cause human malaria, but Plasmodium falciparum infections are responsible for most of the deaths (12). Currently, artemisinin-based combination therapies (ACTs) are the recommended treatment for uncomplicated malaria in all regions in which the disease is endemic (13). ACTs appeared as a solution for drug-resistant P. falciparum malaria, with rapid elimination of asexual parasites and young gametocytes (14, 15). However, ACTs are ineffective against mature gametocytes, allowing persistent parasite transmission after treatment (16). Besides using potent antimalarial drugs against the blood-stage parasites, blocking through vector control or utilizing transmission-blocking drugs is essential for the effective control of malaria transmission. Insecticide-treated nets and indoor residual spraying are used extensively, although vectors can develop resistance to insecticides (17) or bite in outdoor areas. In addition, the emergence of P. falciparum parasites that are less susceptible to artemisinin derivatives, especially in Southeast Asia (14, 18), calls for the development of new antimalarial drugs and demonstrates the need for additional methods to complement malaria control. Recently, several studies investigated the potential of ivermectin for malaria control, especially focusing on its capacity to inhibit parasite transmission (19–21) and sporogony (22–24) and its insecticidal activity (25–29). However, in vitro studies regarding the effects of ivermectin against the sexual and asexual stages of the parasite are still lacking. Thus, the aim of this study was to investigate the in vitro activity of ivermectin against asexual and mature gametocyte stages of P. falciparum.

RESULTS

Ivermectin inhibits the development of asexual parasites at nanomolar concentrations.Ivermectin was active against all tested laboratory strains and clinical isolates, with a 50% inhibitory concentration (IC50) of ∼100 nM (Table 1). The clinical isolate JH1 was approximately 5 times more sensitive and the K1 strain was 3 times more resistant to ivermectin than the other tested strains. This effect was not correlated with chloroquine resistance. Ivermectin had dose-dependent activities against all parasite strains. Drastic parasite growth inhibition occurred with all strains (Fig. 1).

View this table:
  • View inline
  • View popup
TABLE 1

Results of the asexual growth inhibition assay for chloroquine and ivermectin, presented as IC50 values

FIG 1
  • Open in new tab
  • Download powerpoint
FIG 1

Inhibition curves for different Plasmodium falciparum strains in the presence of ivermectin. Mean inhibition curves with SDs for laboratory strains (a) and clinical isolates (b) are shown.

Ivermectin arrests the parasite cycle at the trophozoite stage.Samples were collected every 12 h and subsequently were stained and examined by light microscopy, to investigate the effect of ivermectin on the intracellular parasites. As shown in Fig. 2, the assay started (0 h) when the synchronized parasite culture was at the ring (Fig. 2a.1), trophozoite (Fig. 2c.1), or schizont (Fig. 2e.1) stage. Ivermectin-treated ring-stage parasites arrested development at the trophozoite stage, as can be seen in Fig. 2b.2. Controls, i.e., parasites without drug, developed normally through the cycle (rings, trophozoites, schizonts, and rings again) (Fig. 2a.1 to a.7) until the end of the assay (72 h). In comparison, the parasites treated with 100 nM ivermectin developed to trophozoites but were not able to transform into schizonts, presenting a pyknotic morphology until the end of the assay (Fig. 2b.3 to b.7).

FIG 2
  • Open in new tab
  • Download powerpoint
FIG 2

Light microscopy of parasite cultures. Synchronized stages of Plasmodium falciparum strain 3D7 were treated with ivermectin for 72 h. Samples were evaluated by microscopy every 12 h until 72 h, to observe the parasites’ morphology. Untreated parasites in the ring (a.1 to a.7), trophozoite (c.1 to c.7), or schizont (e.1 to e.7) stage were maintained in parallel. Ivermectin-treated ring-stage parasites became trophozoites, but parasites did not develop further to schizonts (b.2 to b.7). Ivermectin-treated trophozoites arrested their life cycle, not completing maturation to schizonts (d.2 to d.7). Schizonts treated with ivermectin released merozoites to infect new erythrocytes; the merozoites developed to rings and also arrested at the trophozoite stage (f.2 to f.7). All treated parasites were exposed to 100 nM (∼IC50 value). In summary, ivermectin arrested the parasite cycle at the trophozoite stage, and parasites started to present a condensed and pyknotic morphology.

The same procedures were performed with synchronized trophozoites (Fig. 2c.1 to c.7 and Fig. 2d.2 to d.7) and synchronized schizont-stage parasites (Fig. 2e.1 to e.7 and Fig. 2f.2 to f.7). In all assays, parasites arrested at the trophozoite stage irrespective of the stage that was first subjected to the drug (Fig. 2).

Ivermectin is active against mature gametocytes at nanomolar concentrations.Table 2 shows the IC50 values of the drugs chlorotonil A (internal control), methylene blue and epoxomicin (positive controls), and ivermectin against mature gametocytes, revealing that ivermectin also had some activity against this stage of the parasite, although a 5-fold higher concentration was needed, compared to the asexual assay.

View this table:
  • View inline
  • View popup
TABLE 2

IC50 values for different drugs against mature gametocytes of P. falciparum

DISCUSSION

Ivermectin exhibits unprecedented antiparasitic effects, with activity against helminths, insects, and arachnids (30). Since the approval of the use of ivermectin in humans, the drug has been tested against a variety of human parasitic diseases, as reviewed previously (31, 32), but it was suggested that it was inactive against bacteria, fungi, flatworms, and protozoans (33). However, recent publications described in vitro activity of ivermectin against flavivirus (34), bacterial species (35–37), Toxoplasma gondii (38), and Trypanosoma brucei (39).

Recently, ivermectin was discovered as a potential drug for malaria transmission control (8, 19, 40–42) and it has been investigated due to its insecticidal effects (25–27, 43) and its ability to inhibit Plasmodium sporogony (24). Additionally, ivermectin was tested against Plasmodium berghei liver stages in vitro and in vivo (44); it inhibited the development and replication of the parasite inside human hepatoma cells (Huh7) in vitro with an IC50 of ∼2 μM (2.1 μg/ml). In addition, ivermectin reduced the P. berghei liver infection in mice by 80% after 46 h of treatment with three doses of 10 mg/kg. Overall, it was stated that ivermectin impaired liver-stage development of P. berghei and subsequently decreased the blood parasite burden, thereby improving survival time for infected mice.

Despite many studies investigating ivermectin as a promising drug for malaria transmission control, there are few available data regarding the in vitro effects of ivermectin on asexual and sexual P. falciparum stages. One group tested ivermectin in vitro against the P. falciparum K1 strain and found only low activity (IC50 of 8 μg/ml, corresponding to 9.1 μM) (45). However, the present study showed a higher activity of ivermectin against parasites of the K1 strain, with an IC50 value of 365 nM, which is 24 times less than the concentration observed previously. Differences with respect to our results might be partly explained by methodological differences, e.g., differences in measurement of parasite viability (hypoxanthine assay versus histidine-rich protein 2 [HRP2] assay), addition of the drug (dissolved in methanol and dried versus diluted in dimethyl sulfoxide [DMSO] followed by complete culture medium), and parasitemia conditions. No other publications assessing the in vitro activity of ivermectin against P. falciparum are available. Panchal and collaborators (46) evaluated the mode of action of ivermectin against P. falciparum laboratory strains (3D7 and Dd2) when investigating the effects of nuclear import/export inhibitors on P. falciparum signal recognition particles (SRPs). They used concentrations ranging from 10 to 25 μM for 24 h but did not determine IC50 values. We found in vitro activity of ivermectin against the intraerythrocytic stages of both laboratory strains and three clinical strains isolated in Gabon (JH1, JH13, and JH26) at nanomolar concentrations (Table 1). In addition, some activity against mature gametocytes (NF-54 strain) was seen (Table 2).

The intraerythrocytic cycle of P. falciparum takes approximately 48 h, during which it shows different morphological stages, including the ring stage, the trophozoite stage (the most metabolically active stage), and the multinucleated schizont stage (47). The present study suggests that ivermectin is stage specific, arresting the parasites’ life cycle at the trophozoite stage, when they become pyknotic, and inhibiting their development into schizonts. Schizont maturation and merozoite invasion of uninfected erythrocytes seemed microscopically not to be affected. This arresting effect was also seen by Panchal et al. (46), which suggested that this effect on parasite growth could be attributed to the blockage of nucleocytoplasmic shuttling of SRP polypeptides, avoiding the signal sequence recognition needed for protein synthesis. Most of the drugs used against Plasmodium sp., such as chloroquine, amodiaquine, mefloquine, and piperaquine, target trophozoites (48–50). Artemisinins additionally target ring stages as well as schizonts, so that all asexual blood stages are affected (49, 50). Hemoglobin-digesting parasite stages also presented a condensed and pyknotic morphology after treatment with chloroquine and artemisinin (47).

Most antimalarial drugs have no activity against mature gametocytes, allowing the transmission of malaria after treatment (51). The administration of drugs such as mepacrine, quinine, and sulfadoxine-pyrimethamine has been associated with the stimulation of gametocytemia, potentially increasing transmission to mosquitoes (52, 53). Other drugs, such as artemisinin and atovaquone, are known to be effective only against early gametocyte stages (54–56). Only a few compounds have shown effects against mature gametocytes in vivo in humans, including methylene blue (57), the 8-aminoquinoline primaquine (58), and tafenoquine (16). The mode of action of primaquine in gametocytes is unclear, but it has been suggested that it targets mitochondrial function (59). The observed in vitro activity of ivermectin against mature gametocytes probably will not translate into pronounced in vivo activity, as the necessary plasma levels will not be reached due to dosing constraints. However, the prominent activity against blood-sucking mosquitoes might be complemented and affect transmission.

Pharmacokinetic studies showed that, after oral administration of the recommended ivermectin dose in humans (200 μg/kg), the concentration in plasma reaches 50 ng/ml (60), a concentration that would not have a major impact on parasite survival, according to our in vitro data. In this study, the IC50 values against the asexual stages for most of the parasite strains were ∼100 nM, corresponding to 87 ng/ml. However, plasma levels of ivermectin can vary greatly, depending on drug administration conditions. When a high-fat meal is given immediately before ivermectin administration, the drug absorption increases (61, 62). A concentration above the IC50 could be maintained for 12 h when a single oral dose of 30 mg of ivermectin was given with food (61); therefore, the in vitro inhibitory effects could be translated to in vivo effects against the disease-causing asexual stages when the appropriate dosing and administration are used. Moreover, ivermectin availability was greater when the drug was administered in a hydroalcoholic solution, in comparison with a solid capsule formulation or a tablet (63). With the oral dose (400 μg/kg) recommended by French authorities to control lymphatic filariasis (64), ivermectin plasma concentrations could reach up to 260 ng/ml when the drug was given with food, with a time to the maximal plasma concentration of 4.9 ± 1.8 h (61). Guzzo et al. (61) showed that, under fasted conditions, concentrations of 165.2 ± 98.6 ng/ml were reached after administration of one dose of 60 mg ivermectin and concentrations of 186.2 ± 130.8 were detected on day 7 after three doses of 60 mg. Ivermectin has a large volume of distribution (3.1 to 3.5 liters/kg) due to its high lipid solubility and its extensive protein binding (unbound fraction of <0.1), and the peak plasma concentration occurs approximately 4 h after oral dosing, with a second peak at 6 to 12 h, probably arising due to enterohepatic recycling, and a plasma half-life of ∼12 h (60, 65, 66). A recent study investigating the malaria-transmission-blocking potential of ivermectin used concentrations of 300 μg/kg or 600 μg/kg given on 3 consecutive days (total dose of 900 μg/kg or 1,800 μg/kg, respectively) in a fasted state, reaching plasma concentrations of around 69.4 ng/ml (range, 34.1 to 196.3 ng/ml) or 118.9 ng/ml (range, 45.2 to 455.1 ng/ml), respectively, and showed that these doses were well tolerated and reduced mosquito survival rates for at least 28 days after treatment (67, 68). Results from the different pharmacokinetic investigations show that concentrations of ivermectin that affect parasite survival can be reached, depending on the chosen administration method and dosing. Different formulations (for example, slow-release ivermectin) are options that have to be further investigated if ivermectin is to be considered an additional transmission-blocking tool (69).

The ability to decrease mosquito survival rates several days after drug intake is the key advantage of ivermectin in malaria control and can have a huge impact on residual transmission. Some vector species changed their behavior to evade the indoor residual spraying of insecticides and the use of long-lasting insecticidal nets. Although these two methods are efficient in controlling malaria transmission while humans are asleep indoors at night, atypical attacks on humans in the mornings or evenings when unprotected people are outdoors allow for residual transmission (70). At this point, ivermectin, although it cannot protect the individual from being bitten, avoids transmission of the parasite (22).

In conclusion, ivermectin showed promising in vitro activity against asexual blood stages of two laboratory (3D7 and Dd2) and three clinical (JH1, JH13, and JH26) P. falciparum strains, in addition to some activity against mature gametocytes. Further investigations are necessary to confirm these results and to determine whether this activity can also be shown in vivo. If this is the case, an additional feature can be appended to the exceptional activity profile of ivermectin, adding to its properties as a complementary tool for malaria control and elimination.

MATERIALS AND METHODS

Chemicals.The positive-control drug for the asexual assay was chloroquine diphosphate (Sigma) and those for the gametocyte assay were epoxomicin (Sigma), methylene blue (Sigma), and chlorotonil A (provided by the Helmholtz Centre for Infection Research and Pharmaceutical Biotechnology, Saarland University, Saarbrücken, Germany) (71). Stock solutions of ivermectin (Sigma product no. I8898; molecular mass of 875.1 g/mol) and epoxomicin were diluted in DMSO at 100 mM and 1 mM, respectively. Methylene blue and chloroquine were dissolved in distilled water at 13 mM and 1 mM, respectively, and chlorotonil A was dissolved in tetrahydrofuran at 2.1 mM. All compounds were first diluted to a stock solution before further dilution in complete medium to reach the desired start concentration. Final solvent concentrations in the assay (<0.1%) did not interfere with parasite growth. Pilot experiments showed that DMSO displays no toxicity when concentrations are <0.5%. The ivermectin used here has the same composition as the ivermectin commonly used for mass drug administration (Mectizan and Stromectol; B1a, ≥90%; B1b, ≤5%).

Asexual stage parasite culture.P. falciparum laboratory strains 3D7 (chloroquine sensitive), Dd2 (chloroquine, sulfadoxine, and pyrimethamine resistant), K1 (chloroquine, sulfadoxine, and pyrimethamine resistant), and NF-54 (provided by Sanaria; a vigorous gametocyte producer) and clinical isolates from Gabon JH1 (chloroquine resistant), JH13 (chloroquine resistant), and JH26 (chloroquine sensitive) (72) were maintained in continuous culture as described previously (73). Briefly, parasites were kept in complete culture medium (RPMI 1640 medium [Sigma], 2 mM l-glutamine [Gibco], 12 ml of 1 M HEPES [Gibco], 50 μg/ml gentamicin [Gibco], and 0.5% [wt/vol] AlbuMax II) at 37°C in 5% CO2/5% O2 at 2.5% hematocrit, with a change of medium every 2 days and with regular parasite dilution with fresh erythrocytes. The 3D7, Dd2, K1, JH1, JH13, and JH26 strains were used in the growth inhibition assays with the asexual stages, while NF-54 was used to produce mature gametocytes. Regular synchronization was performed using magnetic column separation.

Gametocyte culture.Gametocyte culture was performed as described previously (74), with minor modifications. P. falciparum NF-54 strain synchronized ring-stage parasites were used to initiate the gametocyte culture at 6% hematocrit and 0.3% parasitemia. Complete culture medium (as described above) supplemented with 5% human serum was changed daily, without parasite dilution, for 14 days. The medium was doubled when parasitemia reached 5%, and 50 mM N-acetyl-d-glucosamine (MP Biomedicals GmbH) was added between day 11 and day 14, to remove asexual stages. On day 15, when most of the gametocytes had reached maturity (stage IV/V), the gametocytes were purified with a NycoPrep 1.077 cushion density gradient and magnetic column separation, to remove erythrocytes and to concentrate the gametocyte population (75).

In vitro growth inhibition assay for ring-stage asexual P. falciparum parasites.The drug assays were performed as described by Noedl et al. (76). Briefly, ivermectin and chloroquine were distributed in a 3-fold serial dilution in 96-well plates before synchronized ring-stage parasites were diluted to a parasitemia of 0.05% with blood group O Rh factor-positive erythrocytes and were seeded at a hematocrit of 1.5% in a total volume of 225 μl per well. After 72 h, the plates were frozen and thawed three times, and an enzyme-linked immunosorbent assay for measurement of HRP2 was performed using a microplate reader (PHOmo; Autobio). All experiments were performed in duplicate and repeated at least three times.

In vitro activity of compounds against late-stage (stage IV/V) gametocytes of P. falciparum.Drug assays were performed as described previously (75). The compounds (ivermectin, epoxomicin, methylene blue, and chlorotonil A) were precoated in a 3-fold dilution in 96-well plates. Subsequently, the previously purified stage IV/V gametocytes were added to the plate (50,000 gametocytes/well) and incubated at 37°C in 5% CO2/5% O2. After 48 h, the ATP production of gametocytes was measured by the BacTiterGlo assay (Promega), according to the manufacturer’s instructions, and results were quantified using a luminometer (LUmo; Autobio). All experiments were repeated at least three times in duplicate.

Stage-specific activity of ivermectin.To investigate whether the effect of ivermectin was stage specific, the asexual parasites were synchronized to the ring stage using magnetic column separation. The rings were used readily or after the development to trophozoites (18 h) or schizonts (30 h). The stage-specific parasites were seeded in 96-well plates as described above, with modification of the parasitemia (1%) to facilitate observation by light microscopy. Every 12 h of drug incubation, one sample was collected from the control well (no drug) and the 100 nM ivermectin-treated well (IC50 value for 72 h of treatment). Thin blood smears were prepared, fixed in pure methanol for 10 s, and stained in Giemsa (Merck) solution (5%) for 20 min. The samples were visualized using Leica DMBL microscopy, and pictures were taken using a ProgRes C10 camera and software (Jenoptik, Germany), at ×100 magnification.

Statistics.Individual IC50 values were determined by nonlinear regression analysis of log concentration-response curves, using the drc v0.9.0 package (77) of R v2.3.1 (78). Mean IC50 values and standard deviations (SDs) were calculated for each drug assayed in laboratory strains and clinical isolates. Graphical presentation of the drug inhibition data was performed using GraphPad Prism v7.04 for Windows (GraphPad Software, La Jolla, CA, USA).

ACKNOWLEDGMENTS

We acknowledge support by the Conselho Nacional de Pesquisa, with a scholarship to L.P.D.C. Institutional funding supported this work.

We declare no conflicts of interest.

FOOTNOTES

    • Received 14 January 2019.
    • Returned for modification 13 February 2019.
    • Accepted 9 May 2019.
    • Accepted manuscript posted online 20 May 2019.
  • Copyright © 2019 American Society for Microbiology.

All Rights Reserved.

REFERENCES

  1. 1.↵
    1. Campbell WC,
    2. Fisher MH,
    3. Stapley EO,
    4. Albers-Schönberg G,
    5. Jacob TA
    . 1983. Ivermectin: a potent new antiparasitic agent. Science 221:823–828. doi:10.1126/science.6308762.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Crump A
    . 2017. Ivermectin: enigmatic multifaceted “wonder” drug continues to surprise and exceed expectations. J Antibiot (Tokyo) 70:495–505. doi:10.1038/ja.2017.11.
    OpenUrlCrossRef
  3. 3.↵
    1. Omura S,
    2. Crump A
    . 2014. Ivermectin: panacea for resource-poor communities? Trends Parasitol 30:445–455. doi:10.1016/j.pt.2014.07.005.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Zouré HGM,
    2. Noma M,
    3. Tekle AH,
    4. Amazigo UV,
    5. Diggle PJ,
    6. Giorgi E,
    7. Remme JH
    . 2014. The geographic distribution of onchocerciasis in the 20 participating countries of the African Programme for Onchocerciasis Control: (2) pre-control endemicity levels and estimated number infected. Parasit Vectors 7:326. doi:10.1186/1756-3305-7-326.
    OpenUrlCrossRef
  5. 5.↵
    1. Crump A,
    2. Ōmura S
    . 2011. Ivermectin, ‘wonder drug’ from Japan: the human use perspective. Proc Jpn Acad Ser B Phys Biol Sci 87:13–28. doi:10.2183/pjab.87.13.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Currie B,
    2. McCarthy J
    . 2010. Permethrin and ivermectin for scabies. N Engl J Med 362:717–725. doi:10.1056/NEJMct0910329.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    1. Chosidow O,
    2. Giraudeau B,
    3. Cottrell J,
    4. Izri A,
    5. Hofmann R,
    6. Mann SG,
    7. Burgess I
    . 2010. Oral ivermectin versus malathion lotion for difficult-to-treat head lice. N Engl J Med 362:896–905. doi:10.1056/NEJMoa0905471.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    1. Foy BD,
    2. Kobylinski KC,
    3. da Silva IM,
    4. Rasgon JL,
    5. Sylla M
    . 2011. Endectocides for malaria control. Trends Parasitol 27:423–428. doi:10.1016/j.pt.2011.05.007.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    1. Chaccour C,
    2. Rabinovich NR
    . 2017. Ivermectin to reduce malaria transmission. III. Considerations regarding regulatory and policy pathways. Malar J 16:162. doi:10.1186/s12936-017-1803-2.
    OpenUrlCrossRef
  10. 10.↵
    World Health Organization. 2017. Guidelines for the treatment of malaria, 3rd ed. World Health Organization, Geneva, Switzerland.
  11. 11.↵
    1. White NJ,
    2. Pukrittayakamee S,
    3. Hien TT,
    4. Faiz MA,
    5. Mokuolu OA,
    6. Dondorp AM
    . 2014. Malaria. Lancet 383:723–735. doi:10.1016/S0140-6736(13)60024-0.
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    1. Lu XM,
    2. Batugedara G,
    3. Lee M,
    4. Prudhomme J,
    5. Bunnik EM,
    6. Le Roch KG
    . 2017. Nascent RNA sequencing reveals mechanisms of gene regulation in the human malaria parasite Plasmodium falciparum. Nucleic Acids Res 45:7825–7840. doi:10.1093/nar/gkx464.
    OpenUrlCrossRef
  13. 13.↵
    1. Cui L,
    2. Mharakurwa S,
    3. Ndiaye D,
    4. Rathod PK,
    5. Rosenthal PJ
    . 2015. Antimalarial drug resistance: literature review and activities and findings of the ICEMR Network. Am J Trop Med Hyg 93(Suppl):57–68. doi:10.4269/ajtmh.15-0007.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Blasco B,
    2. Leroy D,
    3. Fidock DA
    . 2017. Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic. Nat Med 23:917–928. doi:10.1038/nm.4381.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Thu AM,
    2. Phyo AP,
    3. Landier J,
    4. Parker DM,
    5. Nosten FH
    . 2017. Combating multidrug-resistant Plasmodium falciparum malaria. FEBS J 284:2569–2578. doi:10.1111/febs.14127.
    OpenUrlCrossRef
  16. 16.↵
    1. Kemirembe K,
    2. Cabrera M,
    3. Cui L
    . 2017. Interactions between tafenoquine and artemisinin-combination therapy partner drug in asexual and sexual stage Plasmodium falciparum. Int J Parasitol Drugs Drug Resist 7:131–137. doi:10.1016/j.ijpddr.2017.03.002.
    OpenUrlCrossRef
  17. 17.↵
    1. Ondeto BM,
    2. Nyundo C,
    3. Kamau L,
    4. Muriu SM,
    5. Mwangangi JM,
    6. Njagi K,
    7. Mathenge EM,
    8. Ochanda H,
    9. Mbogo CM
    . 2017. Current status of insecticide resistance among malaria vectors in Kenya. Parasit Vectors 10:429. doi:10.1186/s13071-017-2361-8.
    OpenUrlCrossRef
  18. 18.↵
    1. Antony H,
    2. Parija S
    . 2016. Antimalarial drug resistance: an overview. Trop Parasitol 6:30. doi:10.4103/2229-5070.175081.
    OpenUrlCrossRef
  19. 19.↵
    1. Alout H,
    2. Krajacich BJ,
    3. Meyers JI,
    4. Grubaugh ND,
    5. Brackney DE,
    6. Kobylinski KC,
    7. Diclaro JW, II,
    8. Bolay FK,
    9. Fakoli LS,
    10. Diabaté A,
    11. Dabiré RK,
    12. Bougma RW,
    13. Foy BD
    . 2014. Evaluation of ivermectin mass drug administration for malaria transmission control across different West African environments. Malar J 13:417. doi:10.1186/1475-2875-13-417.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Kobylinski KC,
    2. Alout H,
    3. Foy BD,
    4. Clements A,
    5. Adisakwattana P,
    6. Swierczewski BE,
    7. Richardson JH
    . 2014. Rationale for the coadministration of albendazole and ivermectin to humans for malaria parasite transmission control. Am J Trop Med Hyg 91:655–662. doi:10.4269/ajtmh.14-0187.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Kobylinski KC,
    2. Sylla M,
    3. Chapman PL,
    4. Sarr MD,
    5. Foy BD
    . 2011. Ivermectin mass drug administration to humans disrupts malaria parasite transmission in Senegalese villages. Am J Trop Med Hyg 85:3–5. doi:10.4269/ajtmh.2011.11-0160.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Pinilla YT,
    2. Lopes SCP,
    3. Sampaio VS,
    4. Andrade FS,
    5. Melo GC,
    6. Orfanó AS,
    7. Secundino NFC,
    8. Guerra MGVB,
    9. Lacerda MVG,
    10. Kobylinski KC,
    11. Escobedo-Vargas KS,
    12. López-Sifuentes VM,
    13. Stoops CA,
    14. Baldeviano GC,
    15. Tarning J,
    16. Vasquez GM,
    17. Pimenta PFP,
    18. Monteiro WM
    . 2018. Promising approach to reducing malaria transmission by ivermectin: sporontocidal effect against Plasmodium vivax in the South American vectors Anopheles aquasalis and Anopheles darlingi. PLoS Negl Trop Dis 12:e0006221. doi:10.1371/journal.pntd.0006221.
    OpenUrlCrossRef
  23. 23.↵
    1. Kobylinski KC,
    2. Ubalee R,
    3. Ponlawat A,
    4. Nitatsukprasert C,
    5. Phasomkulsolsil S,
    6. Wattanakul T,
    7. Tarning J,
    8. Na-Bangchang K,
    9. McCardle PW,
    10. Davidson SA,
    11. Richardson JH
    . 2017. Ivermectin susceptibility and sporontocidal effect in Greater Mekong Subregion Anopheles. Malar J 16:280. doi:10.1186/s12936-017-1923-8.
    OpenUrlCrossRef
  24. 24.↵
    1. Kobylinski KC,
    2. Foy BD,
    3. Richardson JH
    . 2012. Ivermectin inhibits the sporogony of Plasmodium falciparum in Anopheles gambiae. Malar J 11:381. doi:10.1186/1475-2875-11-381.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Chaccour C,
    2. Lines J,
    3. Whitty C
    . 2010. Effect of ivermectin on Anopheles gambiae mosquitoes fed on humans: the potential of oral insecticides in malaria control. J Infect Dis 202:113–116. doi:10.1086/653208.
    OpenUrlCrossRefPubMedWeb of Science
  26. 26.↵
    1. Kobylinski KC,
    2. Deus KM,
    3. Butters MP,
    4. Hongyu T,
    5. Gray M,
    6. da Silva IM,
    7. Sylla M,
    8. Foy BD
    . 2010. The effect of oral anthelmintics on the survivorship and re-feeding frequency of anthropophilic mosquito disease vectors. Acta Trop 116:119–126. doi:10.1016/j.actatropica.2010.06.001.
    OpenUrlCrossRefPubMedWeb of Science
  27. 27.↵
    1. Fritz ML,
    2. Walker ED,
    3. Miller JR
    . 2012. Lethal and sublethal effects of avermectin/milbemycin parasiticides on the African malaria vector, Anopheles arabiensis. J Med Entomol 49:326–331. doi:10.1603/ME11098.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Foley DH,
    2. Bryan JH,
    3. Lawrence GW
    . 2000. The potential of ivermectin to control the malaria vector Anopheles farauti. Trans R Soc Trop Med Hyg 94:625–628. doi:10.1016/s0035-9203(00)90211-6.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Sylla M,
    2. Kobylinski KC,
    3. Gray M,
    4. Chapman PL,
    5. Sarr MD,
    6. Rasgon JL,
    7. Foy BD
    . 2010. Mass drug administration of ivermectin in south-eastern Senegal reduces the survivorship of wild-caught, blood fed malaria vectors. Malar J 9:365. doi:10.1186/1475-2875-9-365.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Ōmura S
    . 2016. A splendid gift from the Earth: the origins and impact of the avermectins (Nobel lecture). Angew Chem Int Ed Engl 55:10190–10209. doi:10.1002/anie.201602164.
    OpenUrlCrossRef
  31. 31.↵
    1. Juarez M,
    2. Schcolnik-Cabrera A,
    3. Dueñas-Gonzalez A
    . 2018. The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug. Am J Cancer Res 8:317–331.
    OpenUrl
  32. 32.↵
    1. Campbell WC
    . 1991. Ivermectin as an antiparasitic agent for use in humans. Annu Rev Microbiol 45:445–474. doi:10.1146/annurev.mi.45.100191.002305.
    OpenUrlCrossRefPubMedWeb of Science
  33. 33.↵
    1. Õmura S
    . 2008. Ivermectin: 25 years and still going strong. Int J Antimicrob Agents 31:91–98. doi:10.1016/j.ijantimicag.2007.08.023.
    OpenUrlCrossRefPubMedWeb of Science
  34. 34.↵
    1. Mastrangelo E,
    2. Pezzullo M,
    3. De Burghgraeve T,
    4. Kaptein S,
    5. Pastorino B,
    6. Dallmeier K,
    7. De Lamballerie X,
    8. Neyts J,
    9. Hanson AM,
    10. Frick DN,
    11. Bolognesi M,
    12. Milani M
    . 2012. Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug. J Antimicrob Chemother 67:1884–1894. doi:10.1093/jac/dks147.
    OpenUrlCrossRefPubMedWeb of Science
  35. 35.↵
    1. Ashraf S,
    2. Chaudhry U,
    3. Raza A,
    4. Ghosh D,
    5. Zhao X
    . 2018. In vitro activity of ivermectin against Staphylococcus aureus clinical isolates. Antimicrob Resist Infect Control 7:27. doi:10.1186/s13756-018-0314-4.
    OpenUrlCrossRef
  36. 36.↵
    1. Pettengill MA,
    2. Lam VW,
    3. Ollawa I,
    4. Marques-da-Silva C,
    5. Ojcius DM
    . 2012. Ivermectin inhibits growth of Chlamydia trachomatis in epithelial cells. PLoS One 7:e48456. doi:10.1371/journal.pone.0048456.
    OpenUrlCrossRefPubMed
  37. 37.↵
    1. Lim LE,
    2. Vilchèze C,
    3. Ng C,
    4. Jacobs WR,
    5. Ramón-García S,
    6. Thompson CJ
    . 2013. Anthelmintic avermectins kill Mycobacterium tuberculosis, including multidrug-resistant clinical strains. Antimicrob Agents Chemother 57:1040–1046. doi:10.1128/AAC.01696-12.
    OpenUrlAbstract/FREE Full Text
  38. 38.↵
    1. Bilgin M,
    2. Yildirim T,
    3. Hökelek M
    . 2013. In vitro effects of ivermectin and sulphadiazine on Toxoplasma gondii. Balkan Med J 30:19–22. doi:10.5152/balkanmedj.2012.098.
    OpenUrlCrossRef
  39. 39.↵
    1. Udensi UK,
    2. Fagbenro-Beyioku AF
    . 2012. Effect of ivermectin on Trypanosoma brucei brucei in experimentally infected mice. J Vector Borne Dis 49:143–150.
    OpenUrlPubMed
  40. 40.↵
    1. Chaccour C,
    2. Barrio ÁI,
    3. Royo AGG,
    4. Urbistondo DM,
    5. Slater H,
    6. Hammann F,
    7. Del Pozo JL
    . 2015. Screening for an ivermectin slow-release formulation suitable for malaria vector control. Malar J 14:102. doi:10.1186/s12936-015-0618-2.
    OpenUrlCrossRef
  41. 41.↵
    1. Slater HC,
    2. Walker PGT,
    3. Bousema T,
    4. Okell LC,
    5. Ghani AC
    . 2014. The potential impact of adding ivermectin to a mass treatment intervention to reduce malaria transmission: a modelling study. J Infect Dis 210:1972–1980. doi:10.1093/infdis/jiu351.
    OpenUrlCrossRefPubMed
  42. 42.↵
    1. Steketee RW,
    2. ter Kuile FO
    . 2015. Ivermectin as a complementary strategy to kill mosquitoes and stop malaria transmission? Clin Infect Dis 60:366–368. doi:10.1093/cid/ciu802.
    OpenUrlCrossRefPubMed
  43. 43.↵
    1. Tesh RB,
    2. Guzman H
    . 1990. Mortality and infertility in adult mosquitoes after the ingestion of blood containing ivermectin. Am J Trop Med Hyg 43:229–233. doi:10.4269/ajtmh.1990.43.229.
    OpenUrlAbstract/FREE Full Text
  44. 44.↵
    1. Mendes AM,
    2. Albuquerque IS,
    3. Machado M,
    4. Pissarra J,
    5. Meireles P,
    6. Prudêncio M
    . 2017. Inhibition of Plasmodium liver infection by ivermectin. Antimicrob Agents Chemother 61:e02005-16. doi:10.1128/AAC.02005-16.
    OpenUrlAbstract/FREE Full Text
  45. 45.↵
    1. Nasveld P,
    2. Russell B,
    3. Kotecka B,
    4. Rieckmann K
    . 2003. Lack of in vitro effect of ivermectin on Plasmodium falciparum. Southeast Asian J Trop Med Public Health 34:552–553.
    OpenUrlPubMed
  46. 46.↵
    1. Panchal M,
    2. Rawat K,
    3. Kumar G,
    4. Kibria KM,
    5. Singh S,
    6. Kalamuddin M,
    7. Mohmmed A,
    8. Malhotra P,
    9. Tuteja R
    . 2014. Plasmodium falciparum signal recognition particle components and anti-parasitic effect of ivermectin in blocking nucleo-cytoplasmic shuttling of SRP. Cell Death Dis 5:e994. doi:10.1038/cddis.2013.521.
    OpenUrlCrossRef
  47. 47.↵
    1. Klonis N,
    2. Crespo-Ortiz MP,
    3. Bottova I,
    4. Abu-Bakar N,
    5. Kenny S,
    6. Rosenthal PJ,
    7. Tilley L
    . 2011. Artemisinin activity against Plasmodium falciparum requires hemoglobin uptake and digestion. Proc Natl Acad Sci U S A 108:11405–11410. doi:10.1073/pnas.1104063108.
    OpenUrlAbstract/FREE Full Text
  48. 48.↵
    1. Slater A
    . 1993. Chloroquine: mechanism of drug action and resistance in Plasmodium falciparum. Pharmacol Ther 57:203–235. doi:10.1016/0163-7258(93)90056-J.
    OpenUrlCrossRefPubMedWeb of Science
  49. 49.↵
    1. Bray P,
    2. Park B,
    3. Asadollaly E,
    4. Biagini G,
    5. Jeyadevan J,
    6. Berry N,
    7. Ward S,
    8. O' Neill P
    . 2006. A medicinal chemistry perspective on 4-aminoquinoline antimalarial drugs. Curr Top Med Chem 6:479–507. doi:10.2174/156802606776743147.
    OpenUrlCrossRefPubMed
  50. 50.↵
    1. Wilson DW,
    2. Langer C,
    3. Goodman CD,
    4. McFadden GI,
    5. Beeson JG
    . 2013. Defining the timing of action of antimalarial drugs against Plasmodium falciparum. Antimicrob Agents Chemother 57:1455–1467. doi:10.1128/AAC.01881-12.
    OpenUrlAbstract/FREE Full Text
  51. 51.↵
    1. Schneider P,
    2. Bousema JT,
    3. Gouagna LC,
    4. Otieno S,
    5. van de Vegte-Bolmer M,
    6. Omar SA,
    7. Sauerwein RW
    . 2007. Submicroscopic Plasmodium falciparum gametocyte densities frequently result in mosquito infection. Am J Trop Med Hyg 76:470–474. doi:10.4269/ajtmh.2007.76.470.
    OpenUrlAbstract/FREE Full Text
  52. 52.↵
    1. Baker DA
    . 2010. Malaria gametocytogenesis. Mol Biochem Parasitol 172:57–65. doi:10.1016/j.molbiopara.2010.03.019.
    OpenUrlCrossRefPubMedWeb of Science
  53. 53.↵
    1. Robert V,
    2. Awono-Ambene HP,
    3. Le Hesran JY,
    4. Trape JF
    . 2000. Gametocytemia and infectivity to mosquitoes of patients with uncomplicated Plasmodium falciparum malaria attacks treated with chloroquine or sulfadoxine plus pyrimethamine. Am J Trop Med Hyg 62:210–216. doi:10.4269/ajtmh.2000.62.210.
    OpenUrlAbstract
  54. 54.↵
    1. Fleck SL,
    2. Pudney M,
    3. Sinden RE
    . 1996. The effect of atovaquone (566C80) on the maturation and viability of Plasmodium falciparum gametocytes in vitro. Trans R Soc Trop Med Hyg 90:309–312. doi:10.1016/s0035-9203(96)90266-7.
    OpenUrlCrossRefPubMed
  55. 55.↵
    1. Smalley ME,
    2. Sinden RE
    . 1977. Plasmodium falciparum gametocytes: their longevity and infectivity. Parasitology 74:1–8. doi:10.1017/S0031182000047478.
    OpenUrlCrossRefPubMedWeb of Science
  56. 56.↵
    1. Price RN,
    2. Nosten F,
    3. Luxemburger C,
    4. ter Kuile FO,
    5. Paiphun L,
    6. Chongsuphajaisiddhi T,
    7. White NJ
    . 1996. Effects of artemisinin derivatives on malaria transmissibility. Lancet 347:1654–1658. doi:10.1016/S0140-6736(96)91488-9.
    OpenUrlCrossRefPubMedWeb of Science
  57. 57.↵
    1. Adjalley SH,
    2. Johnston GL,
    3. Li T,
    4. Eastman RT,
    5. Ekland EH,
    6. Eappen AG,
    7. Richman A,
    8. Sim BKL,
    9. Lee MCS,
    10. Hoffman SL,
    11. Fidock DA
    . 2011. Quantitative assessment of Plasmodium falciparum sexual development reveals potent transmission-blocking activity by methylene blue. Proc Natl Acad Sci U S A 108:E1214–E1223. doi:10.1073/pnas.1112037108.
    OpenUrlAbstract/FREE Full Text
  58. 58.↵
    1. Lin JT,
    2. Lon C,
    3. Spring MD,
    4. Sok S,
    5. Chann S,
    6. Ittiverakul M,
    7. Kuntawunginn W,
    8. My M,
    9. Thay K,
    10. Rahman R,
    11. Balasubramanian S,
    12. Char M,
    13. Lanteri CA,
    14. Gosi P,
    15. Ubalee R,
    16. Meshnick SR,
    17. Saunders DL
    . 2017. Single dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission in Cambodia: an open-label randomized trial. PLoS One 12:e0168702. doi:10.1371/journal.pone.0168702.
    OpenUrlCrossRef
  59. 59.↵
    1. Vale N,
    2. Moreira R,
    3. Gomes P
    . 2009. Primaquine revisited six decades after its discovery. Eur J Med Chem 44:937–953. doi:10.1016/j.ejmech.2008.08.011.
    OpenUrlCrossRefPubMed
  60. 60.↵
    1. González Canga A,
    2. Sahagún Prieto AM,
    3. Diez Liébana MJ,
    4. Fernández Martínez N,
    5. Sierra Vega M,
    6. García Vieitez JJ
    . 2008. The pharmacokinetics and interactions of ivermectin in humans: a mini-review. AAPS J 10:42–46. doi:10.1208/s12248-007-9000-9.
    OpenUrlCrossRefPubMedWeb of Science
  61. 61.↵
    1. Guzzo CA,
    2. Furtek CI,
    3. Porras AG,
    4. Chen C,
    5. Tipping R,
    6. Clineschmidt CM,
    7. Sciberras DG,
    8. Hsieh JYK,
    9. Lasseter KC
    . 2002. Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J Clin Pharmacol 42:1122–1133. doi:10.1177/009127002401382731.
    OpenUrlCrossRefPubMedWeb of Science
  62. 62.↵
    1. Miyajima A,
    2. Hirota T,
    3. Sugioka A,
    4. Fukuzawa M,
    5. Sekine M,
    6. Yamamoto Y,
    7. Yoshimasu T,
    8. Kigure A,
    9. Anata T,
    10. Noguchi W,
    11. Akagi K,
    12. Komoda M
    . 2016. Effect of high-fat meal intake on the pharmacokinetic profile of ivermectin in Japanese patients with scabies. J Dermatol 43:1030–1036. doi:10.1111/1346-8138.13321.
    OpenUrlCrossRef
  63. 63.↵
    1. Edwards G,
    2. Dingsdale A,
    3. Helsby N,
    4. Orme MLE,
    5. Breckenridge AM
    . 1988. The relative systemic availability of ivermectin after administration as capsule, tablet, and oral solution. Eur J Clin Pharmacol 35:681–684. doi:10.1007/BF00637608.
    OpenUrlCrossRefPubMedWeb of Science
  64. 64.↵
    Base de Données Publique des Médicaments. 2017. Résumé des caractéristiques du produit: Stromectol 3 mg, comprimé pelliculé. http://base-donnees-publique.medicaments.gouv.fr/affichageDoc.php?specid=61350360&typedoc=R.
  65. 65.↵
    1. Omura S,
    2. Crump A
    . 2017. Ivermectin and malaria control. Malar J 16:172. doi:10.1186/s12936-017-1825-9.
    OpenUrlCrossRef
  66. 66.↵
    1. Baraka OZ,
    2. Mahmoud BM,
    3. Marschke CK,
    4. Geary TG,
    5. Homeida MM,
    6. Williams JF
    . 1996. Ivermectin distribution in the plasma and tissues of patients infected with Onchocerca volvulus. Eur J Clin Pharmacol 50:407–410. doi:10.1007/s002280050131.
    OpenUrlCrossRefPubMedWeb of Science
  67. 67.↵
    1. Smit MR,
    2. Ochomo EO,
    3. Waterhouse D,
    4. Kwambai TK,
    5. Abong'o BO,
    6. Bousema T,
    7. Bayoh NM,
    8. Gimnig JE,
    9. Samuels AM,
    10. Desai MR,
    11. Phillips‐Howard PA,
    12. Kariuki SK,
    13. Wang D,
    14. ter Kuile FO,
    15. Ward SA,
    16. Aljayyoussi G
    . 2019. Pharmacokinetics-pharmacodynamics of high-dose ivermectin with dihydroartemisinin-piperaquine on mosquitocidal activity and QT-prolongation (Ivermal). Clin Pharmacol Ther 105:388–401. doi:10.1002/cpt.1219.
    OpenUrlCrossRef
  68. 68.↵
    1. Smit MR,
    2. Ochomo EO,
    3. Aljayyoussi G,
    4. Kwambai TK,
    5. Abong'o BO,
    6. Chen T,
    7. Bousema T,
    8. Slater HC,
    9. Waterhouse D,
    10. Bayoh NM,
    11. Gimnig JE,
    12. Samuels AM,
    13. Desai MR,
    14. Phillips-Howard PA,
    15. Kariuki SK,
    16. Wang D,
    17. Ward SA,
    18. ter Kuile FO
    . 2018. Safety and mosquitocidal efficacy of high-dose ivermectin when co-administered with dihydroartemisinin-piperaquine in Kenyan adults with uncomplicated malaria (Ivermal): a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis 18:615–626. doi:10.1016/S1473-3099(18)30163-4.
    OpenUrlCrossRef
  69. 69.↵
    1. Chaccour C,
    2. Abizanda G,
    3. Irigoyen Á,
    4. Del Pozo JL
    . 2017. Pilot study of a slow-release ivermectin formulation for malaria control in a pig model. Antimicrob Agents Chemother 61:e02104-16. doi:10.1128/AAC.02104-16.
    OpenUrlFREE Full Text
  70. 70.↵
    1. Killeen GF,
    2. Chitnis N
    . 2014. Potential causes and consequences of behavioural resilience and resistance in malaria vector populations: a mathematical modelling analysis. Malar J 13:97. doi:10.1186/1475-2875-13-97.
    OpenUrlCrossRefPubMed
  71. 71.↵
    1. Held J,
    2. Gebru T,
    3. Kalesse M,
    4. Jansen R,
    5. Gerth K,
    6. Müller R,
    7. Mordmüller B
    . 2014. Antimalarial activity of the myxobacterial macrolide chlorotonil A. Antimicrob Agents Chemother 58:6378–6384. doi:10.1128/AAC.03326-14.
    OpenUrlAbstract/FREE Full Text
  72. 72.↵
    1. Held J,
    2. Soomro SA,
    3. Kremsner PG,
    4. Jansen FH,
    5. Mordmüller B
    . 2011. In vitro activity of new artemisinin derivatives against Plasmodium falciparum clinical isolates from Gabon. Int J Antimicrob Agents 37:485–488. doi:10.1016/j.ijantimicag.2010.12.022.
    OpenUrlCrossRefPubMed
  73. 73.↵
    1. Trager W,
    2. Jensen JB
    . 1976. Human malaria parasites in continuous culture. Science 193:673–675. doi:10.1126/science.781840.
    OpenUrlAbstract/FREE Full Text
  74. 74.↵
    1. Lelièvre J,
    2. Almela MJ,
    3. Lozano S,
    4. Miguel C,
    5. Franco V,
    6. Leroy D,
    7. Herreros E
    . 2012. Activity of clinically relevant antimalarial drugs on Plasmodium falciparum mature gametocytes in an ATP bioluminescence “transmission blocking” assay. PLoS One 7:e35019. doi:10.1371/journal.pone.0035019.
    OpenUrlCrossRefPubMed
  75. 75.↵
    1. Gebru T,
    2. Mordmüller B,
    3. Held J
    . 2014. Effect of fluorescent dyes on in vitro-differentiated, late-stage Plasmodium falciparum gametocytes. Antimicrob Agents Chemother 58:7398–7404. doi:10.1128/AAC.03772-14.
    OpenUrlAbstract/FREE Full Text
  76. 76.↵
    1. Noedl H,
    2. Bronnert J,
    3. Yingyuen K,
    4. Attlmayr B,
    5. Kollaritsch H,
    6. Fukuda M
    . 2005. Simple histidine-rich protein 2 double-site sandwich enzyme-linked immunosorbent assay for use in malaria drug sensitivity testing. Antimicrob Agents Chemother 49:3575–3577. doi:10.1128/AAC.49.8.3575-3577.2005.
    OpenUrlAbstract/FREE Full Text
  77. 77.↵
    1. Ritz C,
    2. Streibig JC
    . 2005. Bioassay analysis using R. J Stat Softw 12:1–22. doi:10.18637/jss.v012.i05.
    OpenUrlCrossRefPubMed
  78. 78.↵
    R Core Team. 2014. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. http://www.R-project.org.
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
Ivermectin Impairs the Development of Sexual and Asexual Stages of Plasmodium falciparum In Vitro
Lais Pessanha de Carvalho, Thaisa Lucas Sandri, Edésio José Tenório de Melo, Rolf Fendel, Peter G. Kremsner, Benjamin Mordmüller, Jana Held
Antimicrobial Agents and Chemotherapy Jul 2019, 63 (8) e00085-19; DOI: 10.1128/AAC.00085-19

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Ivermectin Impairs the Development of Sexual and Asexual Stages of Plasmodium falciparum In Vitro
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Ivermectin Impairs the Development of Sexual and Asexual Stages of Plasmodium falciparum In Vitro
Lais Pessanha de Carvalho, Thaisa Lucas Sandri, Edésio José Tenório de Melo, Rolf Fendel, Peter G. Kremsner, Benjamin Mordmüller, Jana Held
Antimicrobial Agents and Chemotherapy Jul 2019, 63 (8) e00085-19; DOI: 10.1128/AAC.00085-19
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • INTRODUCTION
    • RESULTS
    • DISCUSSION
    • MATERIALS AND METHODS
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Plasmodium falciparum
antimalarial agents
gametocyte

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596